Q1 2026 Recordati Industria Chimica e Farmaceutica SpA Earnings Call Transcript

May 13, 2026 / 12:00 PM GMT

Release Date Price: €51.8 (+3.97%)

Transcript

Key Points

Positve

Recordati SpA (RCDTF) reported a strong start to 2026 with net revenue reaching EUR 730 million, up 4.9% year-on-year, or 8.7% at constant exchange rates.
The rare disease business showed exceptional performance with revenues of $292 million, up 14.8% year-on-year, driven by strong growth in endocrinology and hemo-oncology.
EBITDA increased by 5% to $284 million, with a sector-leading margin of 39.7%, supported by strong operating performance and disciplined cost management.
The company generated $92 million of free cash flow in the quarter, maintaining leverage just below 2 times, providing solid financial flexibility.
Recordati SpA (RCDTF) is advancing its R&D pipeline, with significant progress in clinical trials, including the Phase II trial of prasirerotide and the advancement of sirtumilab into Phase III.

Negative

FX had an adverse impact of 4.3% on revenue, largely due to the US dollar.
The metabolic segment showed softer performance year-on-year, primarily due to lower panhematin demand in the U.S. and phasing effects.
Specialty and Primary Care (SPC) revenue declined 1% year-on-year to $404 million, impacted by a weaker cough and cold season.
In Germany, revenues declined 6.9% year-on-year, mainly due to the decision to exit unprofitable tenders.
Free cash flow was lower year-on-year due to higher working capital absorption and income taxes paid.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RECI.MI - Recordati Industria Chimica e Farmaceutica SpA
Q1 2026 Recordati Industria Chimica e Farmaceutica SpA Earnings Call
May 13, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, this is the Corusco conference operator. Welcome and thank you for joining the Recordati first quarter 2026 results conference call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Ms. Eugenia Litz, Investor Relations of Recordetti. Please go ahead with them.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.